구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | huCART19 (Autologous, humanized anti-CD19 CAR T cell therapy, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)) Stephan Grupp MD PhD·CD19 13 trials |
|---|---|
Overview Program | Autologous, humanized anti-CD19 CAR T cell therapy (huCART19) |
Overview Company | Stephan Grupp MD PhD |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | biomarker analyses (eg, circulating CAR T cells, cytokines, chemokines) |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.. Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) CAR T-cell product (huCART19-IL18) that secretes interleukin-18 to enhance antitumor activity. In this study, we assessed the safety, … |
Toxicology CRS | Reported |
Clinical Safety signal | Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.. Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) CAR T-cell product (huCART19-IL18) that secretes interleukin-18 to enhance antitumor activity. In this study, we assessed the safety, … |
Clinical Program phase | PHASE_2 |
Preclinical Animal (cat.) | Mouse |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | huCART19 (Autologous, humanized anti-CD19 CAR T cell therapy, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)) Stephan Grupp MD PhD·CD19 13 trials |
|---|---|
Overview Program | Autologous, humanized anti-CD19 CAR T cell therapy (huCART19) |
Overview Company | Stephan Grupp MD PhD |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | biomarker analyses (eg, circulating CAR T cells, cytokines, chemokines) |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.. Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) CAR T-cell product (huCART19-IL18) that secretes interleukin-18 to enhance antitumor activity. In this study, we assessed the safety, … |
Toxicology CRS | Reported |
Clinical Safety signal | Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.. Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) CAR T-cell product (huCART19-IL18) that secretes interleukin-18 to enhance antitumor activity. In this study, we assessed the safety, … |
Clinical Program phase | PHASE_2 |
Preclinical Animal (cat.) | Mouse |
추천 비교
추천 비교